Informative Links

Healthcare Links

NYU Langone Health Blood and Marrow Transplant Program

The team at NYU Langone’s Blood and Marrow Transplant Program, part of Perlmutter Cancer Center, includes highly trained physicians who specialize in blood and marrow transplantation. The team also includes transplantation coordinators, social workers, nutritionists, and other experts from multiple specialties, who work together to provide comprehensive care.  Read more...

Educational links

Asbestos and Leukemia

According to data gathered by the National Cancer Institute in 2019, around 61,780 new cases of leukemia are diagnosed in the U.S. each year. The five-year survival rate is approximately 60.7%. This cancer occurs most commonly in people over 66 years old. Repeated exposure to hazardous substances appears to be one risk factor for leukemia. Workers in industrial settings, such as asbestos workers, tire repair workers and soybean farmers, are considered to be at especially high risk for developing leukemia because of occupational exposure to toxic materials.  Read more...

Mesothelioma Veterans Center

The Mesothelioma Veterans Center provides information about treatment, clinical trials, and VA benefits to veterans suffering from asbestos-related illnesses. They’ve had the honor of helping hundreds of veterans pursue compensation after developing mesothelioma or asbestos-related lung cancer from their asbestos exposure in the military.  Read more...

Milestone reached in new leukemia drug

Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute (DFCI), have developed a new therapy that extended the survival of mice with acute myeloid leukemia. The scientists are the first to demonstrate the anti-cancer effect of blocking the Salt-Inducible Kinase 3 (SIK3) pathway in leukemia using YKL-05-099, a drug developed within the lab of Nathanael Gray at DFCI. SIK3 is a kinase that controls cell division and survival of leukemia cells. Blocking SIK3 prevents leukemia cells from growing.  Read more...

MSK Program Focuses on Speeding Up Development of New Leukemia Treatments

On September 3, 2019, Memorial Sloan Kettering launched the Center for Drug Development in Leukemia (CDD-L). This new program will focus on creating more phase I clinical trials for most types of leukemia in adults. Its goal is to rapidly bring novel therapies to people being treated at MSK.  Read more...

Leukemia: Survival Rates and Prognosis

Leukemia is cancer that affects blood cells. There are several types and subtypes of leukemia, and each of them strikes different types of blood cells. The chance of recovering from this cancer - called your prognosis - depends greatly on the specific type of leukemia.  Read more...

Pediatric Leukemia Treatments Are Not Just for Kids

Adolescent and young adult (AYA) ​cancer patients ​​are in a unique position - not children anymore but, in many cases, also not fully grown. Oncologists initially believed it was best to treat patients in this age group as adults. Then research indicated that these patients often had better outcomes when treated at pediatric hospitals.  Read more...

Blood Cancer Discovery

Blood Cancer Discovery, a journal set for release in 2020, will provide a critical outlet for high-impact basic, translational, and clinical research on all disease subtypes of leukemia, lymphoma, myeloma, and associated diseases.  Read more...

Miscellaneous links

Bram Stoker's Vampire Victim Shows 'Textbook' Leukemia Symptoms

Victims of vampire attacks in 19th-century novels didn't just turn pale, swoon and waste away; they displayed a wide range of symptoms that hinted at deadly attacks by a fanged, bloodsucking predator. However, the descriptions of those symptoms were likely grounded in observations of real medical conditions.  Read more...

With your support we can get even closer to a cure

Donate to the CLRA today

DONATE